Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

About this update from Lexeo Therapeutics, Inc.

[{"type":"image","alt":"Lexeo Therapeutics","displaySize":"","headline":null,"caption":"Lexeo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNNLd9kZ10lMRyd7r.aoKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac","width":300,"height":116}},"lazy":false},{"type":"text","content":"NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February:","length":307,"tagName":"p"},{"type":"text","content":"Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY.","length":128,"tagName":"p"},{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat on Thursday, February 26, 2026 at 10:40 a.m. ET (virtual).","length":133,"tagName":"p"},{"type":"text","content":"The events will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcasts will be available on the Lexeo website following the presentations.","length":222,"tagName":"p"},{"type":"text","content":"About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.","length":544,"tagName":"p"},{"type":"text","content":"Media Response:[email protected]","length":33,"tagName":"p"},{"type":"text","content":"Investor Response:Ashley [email protected]","length":58,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]

More updates from Lexeo Therapeutics, Inc.